

FEE TRANSMITTAL

Attorney Docket No.: OPF 10.02	First Named Inventor: POTTER
Application No.: 09/462,218	Filing Date: 6 July 1998
Examiner: K.C. Sirmons	Group Art Unit: 3763

Description of Action

This Fee Transmittal sheet is being submitted in connection with the accompanying Information Disclosure Statement.

Payment of Fees

- ☒ The Assistant Commissioner for Patents is hereby authorized to charge the indicated fees against, and credit any overpayments to the following deposit account. The Assistant Commissioner is further authorized to charge any additional fees required under 37 CFR §§ 1.16 and 1.17 against the same deposit account.

Deposit Account No: **50-0828** Deposit Account Name: **PowderJect Technologies**

Fee Calculations

(1) Filing fee (large entity) (if applicable)

Description	Fee Paid
	(\$)

(2) Extra claim fees (large entity) (if applicable)

Claims in specification as filed

	No. in Specification or after Amendment	No. Included in Filing Fee or Previously Paid For	No. Extra (b)	Applicable Fee	Fee Paid
Total Claims				x 18 (ea.)	
Independent Claims				x 78 (ea.)	
Multiple dependent claim(s) presented for first time (c)				260	
Subtotal (2) Extra claim fees					(\$)

(3) Additional or other fees (large entity) (if applicable)

Description	Fee Paid
Submission of IDS (37 C.F.R. §1.17(p))	180.00
Subtotal (3) Additional or other fees	(\$) 180.00

Total Fees

Total Fees Submitted (Sum of Subtotals (1), (2), and (3))	(\$) 180.00
---	--------------------

I hereby certify that this paper or fee is being deposited with the United States Patent and Trademark Office on the date indicated below:

Date of deposit: June 26, 2003

Name (printed): Jennifer Lohse

Signature: Jennifer Lohse

Respectfully Submitted,

Name: Thomas P. McCracken, Reg. No. 38,548

Tel: +44 1865 332 600

Fax: +44 1865 332 601

Address: PowderJect Pharmaceuticals Plc
Florey House, The Oxford Science Park
Oxford OX4 4GA, United Kingdom

RECEIVED
JUN 26 2003
TECHNOLOGY CENTER 3700

RECEIVED
JUN 27 2003

TECHNOLOGY CENTER R3700

Date of Deposit: June 26, 2003

I hereby certify that this paper and all noted attachments are being hand-deposited with the United States Patent and Trademark Office on the date indicated above.

Jennifer Lohse
Typed or Printed Name of Person Depositing Paper

Jennifer Lohse
Signature of Person Depositing Paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

POTTER et al.

Serial No.: 09/462,218

Art Unit: 3763

Filing Date: 6 July 1998

Examiner: K.C. Simons

Title: SYRINGE AND CAPSULE THEREFOR

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

Commissioner for Patents
Washington, D.C. 20231

Sir:

The information listed below may be material to the examination of the above-identified application. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of

official record in the application. The information includes:

United States Patent No. 5,125,892, to Drudik, issued June 30, 1992;
United States Patent No. 5,614,217, to Chiprich et al., issued March 25, 1997;
United States Patent No. 5,630,796, to Bellhouse et al., issued May 20, 1997;
United States Patent No. 6,004,286, to Bellhouse et al., issued Dec. 21, 1999;
United States Patent No. 6,010,478, to Bellhouse et al., issued Jan. 4, 2000;
United States Patent No. 6,013,050, to Bellhouse et al., issued Jan. 11, 2000;
International Publication No. WO 94/24263, published Oct. 27, 1994;
International Publication No. WO 96/04947, published Feb. 22, 1996;
International Publication No. WO 96/12513, published May 2, 1996;
International Publication No. WO 96/25190, published Aug. 22, 1996;
International Publication No. WO 97/34652, published Sept. 25, 1997;
International Publication No. WO 99/01168, published Jan. 14, 1999;
European Patent Application No. 0144551A1, published June 19, 1985; and
German Patent Application No. 2118993, published Nov. 23, 1972 (no English translation or abstract available).


This Information Disclosure Statement under 37 CFR § 1.97(c) is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

As applicants have received a first Action on the merits, the fee pursuant to 37 C.F.R. §1.17(p) is believed to be required for filing this Disclosure Statement and is being paid with the submission of this Statement. If, for any reason, additional fees are found to be required in connection with this submission, our Deposit Account No. 50-0828 may be charged therefor.

Respectfully submitted,

Date: 19 June 2003

By:



Thomas P. McCracken
Registration No. 38,548

POWDERJECT PHARMACEUTICALS PLC
Florey House
The Oxford Science Park
Oxford OX4 4GA
United Kingdom
Telephone: +44 1865 332 600
Fax: +44 1865 332 601